211 related articles for article (PubMed ID: 15661554)
1. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
Osoba D; Bezjak A; Brundage M; Zee B; Tu D; Pater J;
Eur J Cancer; 2005 Jan; 41(2):280-7. PubMed ID: 15661554
[TBL] [Abstract][Full Text] [Related]
2. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG.
Au HJ; Ringash J; Brundage M; Palmer M; Richardson H; Meyer RM;
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):119-28. PubMed ID: 20384559
[TBL] [Abstract][Full Text] [Related]
3. Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.
Osoba D; Zee B
Stat Med; 1998 Mar 15-Apr 15; 17(5-7):603-12. PubMed ID: 9549809
[TBL] [Abstract][Full Text] [Related]
4. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience.
Osoba D; Bezjak A; Brundage M; Pater J;
Value Health; 2007; 10 Suppl 2():S138-45. PubMed ID: 17995472
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.
Brundage M; Osoba D; Bezjak A; Tu D; Palmer M; Pater J;
J Clin Oncol; 2007 Nov; 25(32):5078-81. PubMed ID: 17991924
[TBL] [Abstract][Full Text] [Related]
6. Reporting of health-related quality of life endpoints in National Cancer Institute-supported cancer treatment trials.
St Germain D; Denicoff A; Torres A; Kelaghan J; McCaskill-Stevens W; Mishkin G; O'Mara A; Minasian LM
Cancer; 2020 Jun; 126(11):2687-2693. PubMed ID: 32237256
[TBL] [Abstract][Full Text] [Related]
7. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
Ediebah DE; Quinten C; Coens C; Ringash J; Dancey J; Zikos E; Gotay C; Brundage M; Tu D; Flechtner HH; Greimel E; Reeve BB; Taphoorn M; Reijneveld J; Dirven L; Bottomley A;
Cancer; 2018 Aug; 124(16):3409-3416. PubMed ID: 29905936
[TBL] [Abstract][Full Text] [Related]
8. Health related quality of life outcomes in cancer clinical trials.
Bottomley A; Flechtner H; Efficace F; Vanvoorden V; Coens C; Therasse P; Velikova G; Blazeby J; Greimel E;
Eur J Cancer; 2005 Aug; 41(12):1697-709. PubMed ID: 16043345
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30.
Pater JL; Zee B; Palmer M; Johnston D; Osoba D
Support Care Cancer; 1997 Sep; 5(5):410-3. PubMed ID: 9322354
[TBL] [Abstract][Full Text] [Related]
11. Causes and Consequences of Missing Health-Related Quality of Life Assessments in Patients Who Undergo Mechanical Circulatory Support Implantation: Insights From INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).
Grady KL; Jones PG; Cristian-Andrei A; Naftel DC; Myers S; Dew MA; Idrissi K; Weidner G; Wissman SA; Kirklin JK; Spertus JA
Circ Cardiovasc Qual Outcomes; 2017 Dec; 10(12):e003268. PubMed ID: 29246883
[TBL] [Abstract][Full Text] [Related]
12. Translating the science of patient-reported outcomes assessment into clinical practice.
Osoba D
J Natl Cancer Inst Monogr; 2007; (37):5-11. PubMed ID: 17951224
[TBL] [Abstract][Full Text] [Related]
13. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis.
Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge LJ; McGrane J; Ng W; King MT
Lancet Oncol; 2011 Dec; 12(13):1240-8. PubMed ID: 21996168
[TBL] [Abstract][Full Text] [Related]
14. Methodology for quality-of-life assessment: a critical appraisal.
Zee BC; Mok TS
Thorac Surg Clin; 2004 Aug; 14(3):305-15. PubMed ID: 15382762
[TBL] [Abstract][Full Text] [Related]
15. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.
Bascoul-Mollevi C; Barbieri A; Bourgier C; Conroy T; Chauffert B; Hebbar M; Jacot W; Juzyna B; De Forges H; Gourgou S; Bonnetain F; Touraine C; Anota A
Qual Life Res; 2021 Jan; 30(1):91-103. PubMed ID: 32809099
[TBL] [Abstract][Full Text] [Related]
17. Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials.
Barbieri A; Peyhardi J; Conroy T; Gourgou S; Lavergne C; Mollevi C
BMC Med Res Methodol; 2017 Sep; 17(1):148. PubMed ID: 28950850
[TBL] [Abstract][Full Text] [Related]
18. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results.
Osoba D
Med Care; 2002 Jun; 40(6 Suppl):III31-8. PubMed ID: 12064756
[TBL] [Abstract][Full Text] [Related]
19. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials.
Hamidou Z; Dabakuyo TS; Bonnetain F
Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):549-59. PubMed ID: 21958100
[TBL] [Abstract][Full Text] [Related]
20. [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].
Fiteni F; Anota A; Westeel V; Bonnetain F
Bull Cancer; 2015 Apr; 102(4):360-6. PubMed ID: 25799875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
